Kerry Inaugurates Leipzig Biotechnology Centre to Advance Pharmaceutical and Food Applications
Key Insights
Kerry (search) has inaugurated the Kerry Biotechnology Centre in Leipzig, Germany, focusing on innovative biotech solutions for food, beverage, and pharmaceutical applications.
The facility will be directed by Dr. Marc Struhalla and employs over 100 scientists including 34 PhDs for enzyme engineering and bioprocess development.
Kerry (search) has successfully commercialized biotech products including DENARASE® (search) for vaccine manufacturing and gene therapies, demonstrating pharmaceutical industry applications.
Kerry (search), a global leader in taste and nutrition, has inaugurated the Kerry Biotechnology Centre in Leipzig, Germany, marking a significant expansion of the company's biotechnology capabilities across food, beverage, and pharmaceutical applications. The new facility represents Kerry's continued investment in biotechnology solutions that address market inefficiencies, ingredient scarcity, and specialized product development needs.
Strategic Location and Leadership
Leipzig was selected for the new biotechnology centre due to the city's exceptional biotechnology skills base and established research cluster. The facility builds upon Kerry (search)'s 2022 acquisition of c-LEcta (search), a specialist enzyme and biotechnology company that was originally established in 2004 as a spin-out from the University of Leipzig (search).
Dr. Marc Struhalla, founder of c-LEcta (search), will direct the new centre, which employs over 100 scientists and technical experts, including 34 PhDs. The facility is aligned with Kerry (search)'s sustainable nutrition strategy and coordinates with the company's Global Innovation Centre in Ireland.
Core Capabilities and Applications
The Leipzig centre will focus on enzyme and strain identification and engineering, fermentation and bioprocess development and scale-up, and production. Novel enzymes are selected from nature and can be tailored to perform specific functions across a broad spectrum of applications.
Kerry (search) has already commercialized several innovative biotech products that demonstrate the pharmaceutical applications of their biotechnology platform. DENARASE® (search) represents a best-in-class enzyme solution designed to remove residual DNA (search) and is utilized in the manufacturing of vaccines and gene and cell therapies. This product highlights Kerry's direct involvement in pharmaceutical manufacturing processes.
Established Product Portfolio
Beyond pharmaceutical applications, Kerry (search)'s biotechnology capabilities have produced ACRYLERASE™ (search), described as a new-to-world enzyme solution capable of removing acrylamide in instant coffee, and BIOBAKE™ (search), enzymes that dramatically increase shelf-life and processability of baked products.
Global Infrastructure and Strategic Vision
Kerry (search)'s biotechnology research and production infrastructure spans three continents, with the Leipzig facility further enhancing this global footprint. The company has significantly developed its biotechnology capabilities through strategic acquisitions and organic investment over the past 20 years.
Kerry (search) CEO Edmond Scanlon emphasized the transformative potential of the new facility: "Biotechnology solutions present a new horizon of innovation and opportunity for global food, beverage and pharmaceutical markets. Kerry's existing portfolio of biotech capabilities, which has been built up over the past 20 years, together with this new Biotechnology Centre, enables us to play a leading role in bringing the next generation of discoveries in this space to market, supporting our customers, as they meet consumer needs for sustainable nutrition."
The inauguration of the Leipzig centre positions Kerry (search) to capitalize on biotechnology's potential to create market innovations that improve efficiency across food production processes while addressing specific pharmaceutical manufacturing needs, particularly in vaccine and gene therapy production.